Headache Disorders, PrimaryIHRSNCT05418218
International Headache Registry Study
An observational study of Headache Disorders, Primary and Headache Disorders, Secondary, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. Read more about this study
- Who is it for?
- Ages 4 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Headache Disorders, Primary, Headache Disorders, Secondary, Migraine
- How many people
- 200,000 participants
- Where
- 1 siteChina
- Study dates
- 12 Jul 2021to 31 Dec 2082
- How long will I take part?
- 60 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 99 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Male or female participants ages 4 to 99 years
Who may be able to join
- The following are requirements for entry into the study:
- Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.
- Male or female participants ages 4 to 99 years, inclusive, at Visit 1.
- Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).
Who cannot join
- Patients who were unable to complete scales such as headache diary.
- Patients denied or unable to be admitted for long-term follow-up.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Kaiming Liu
Hangzhou, Zhejiang, 370001
Kaiming Liu
About this study
Official title: International Headache and Vertigo Registration Study
In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.
Read the detailed description
- Research contents: In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.
- Research target:
We study biomarkers, imaging features, right-to-left shunt of heart (lung), genetic features, real-world treatment studies, and outcomes (in relation to other diseases) for headache and vertigo related diseases.
- Conditions
- Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache, Vertigo, Vestibular Migraine
- Keywords
- Migraine, Headache Disorders, Vertigo, Vestibular Migraine, Fibromyalgia
- Medical subject headings
- Headache Disorders, Primary, Headache Disorders, Secondary, Migraine Disorders, Tension-Type Headache, Vertigo, Fibromyalgia, Headache Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Migraine | Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3. | |
| Other Primary Headache Disorders | Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3. | |
| Vertigo | Patients with other vertigo disorders (excluding vestibular migraine). | |
| Secondary Headache Disorders | Patients with secondary headache disorders as defined by ICHD-3. | |
| Normal control | Normal people do not have headache and vertigo. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Days of Migraine
The number of days of migraine is the number of days in which migraine occurs or is likely to be migraine (according to IHS ICHD-3 diagnostic criteria).
A migraine day is a day when a headache lasts for more than 30 minutes, does not take painkillers, and meets the ICHD-3 migraine or most likely migraine criteria. Migraine day can also be defined as a headache day that is effective for the acute treatment of specific migraine drugs (triptan, ditan, gepant, ergotamine, etc.).
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Moderate / Severe Headache Days
Moderate / severe headache days are defined as a day in which moderate or severe pain persists for at least 4 hours, or headache lasts for one day after successful medication for acute headache. These definitions allow the use of relatively simple headache diaries. Subjects were required to indicate whether headache was present (yes / no), peak (mild / moderate / severe) severity and duration (< 4h or 4h), type of acute drug intake (triptan ergot / other), and response to treatment should also be recorded.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine Attack
Migraine attack is defined as any consistent migraine attacks or the use of specific migraine drugs. If a migraine attack is interrupted by sleep, or temporarily relieved, and then relapses within 48 hours, it is considered an attack. In addition, migraine attacks that were successfully treated with drugs but relapsed within 48 hours and lasted for more than 48 hours were counted as one attack.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Secondary outcomes (26)
The Response Rate of at Least 50%, 75% and 100% Reduction in the Number of Days of Migraine Attacks
The response rate is calculated as the percentage reduction in the frequency of migraine attacks (or days of migraine, or days of moderate or severe headache) compared with the baseline during each treatment period. The response rate is traditionally defined as a reduction of at least 50% from the baseline, but other percentage reductions (for example: 30%, 75%, 100%) may be used.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Headache Intensity
Four-point rating scale was used to evaluate the headache intensity of each migraine day--painless, mild, moderate, or severe. Migraine intensity is not recommended as the main outcome measure alone, but it is important to record the decrease in migraine intensity as an indicator of disability reduction.
Depending on the design of the trial, subjects should be asked to record the intensity of each migraine. In addition, the 11 point visual rating scale (VAS) can be used instead or in combination with the 4-level classification rating scale. The use of VAS in clinical trials may increase the likelihood of showing differences in severity.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Cumulative Hours of Moderate / Severe Pain at 28 Days
The cumulative number of hours of moderate / severe pain calculated by electronic headache diaries. If an attack occurs before going to bed and when you wake up, the amount of sleep also counts as the number of headache hours.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Days Without Symptoms
Defined as the number of days without aura, prodromal symptoms, headaches and subsequent symptoms. It needs to be determined by headache diary.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Days Without Headache
The number of days without headache also includes the number of days without related symptoms directly caused by migraine (including physical function, cognitive or emotional disorders).
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Peak Headache Pain Intensity
Subjects should record the maximum intensity of daily headaches and any medication used. An 11-point digital rating scale can be used instead of or in conjunction with a 4-level classified rating scale.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine Disability Assessment (MIDAS)
MIDAS is a seven-item questionnaire designed to quantify headache-related disability within 3 months. The MIDAS score is the sum of days of absenteeism or absenteeism caused by headache, days of work or school plus days of housework, days without housework and days without non-work activities caused by headache in the last 3 months.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Headache Impact Scale (HIT-6)
HIT-6 is a six-question assessment scale used to assess the effects of headache on subjects' ability to work, school, housework and social tasks. The scale assessed the effects of headache on daily life and the functional ability of the subjects. The answer to the evaluation scale is based on the frequency of use of the 5-point scale from "never" to "often". The total score of HIT-6 ranges from 36 to 78, which is the sum of the scores between 6 (never) and 13 (often) for each question.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine Specific Quality of Life Questionnaire (MSQV2.1)
MSQV2.1 is a 14-item questionnaire used to assess health-related quality of life decline due to migraine in the last 4 weeks. The questionnaire is divided into three areas: the role function limitation area, which is used to assess how migraine restricts the daily social and work-related activities of migraine patients; the role function block area, which is used to assess how migraine prevents these activities; and the emotional function area, which is used to evaluate the emotions associated with migraine. The subjects answered these items using a six-component scale from "never" to "at any time". The original dimension score was calculated by the sum of item answer scores and converted back to 0 to 100. The higher the score, the better the quality of life.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Patient Health Questionnaire (PHQ-9)
PHQ-9 is a validated, self-administered, concise tool for screening and diagnosis of mental health disorders, which has been tested in office practice. The screening scale is easy to use and can be completed in a short time, which improves the recognition rate of depression and facilitates the diagnosis and treatment of depression. PHQ-9 consists of 9 DSM-Ⅳ diagnostic criteria for depression in the last 2 weeks. Subjects were asked to use a 4-component scale to indicate the frequency of 9 depressive symptoms in the last 2 weeks: 0 (none at all), 1 (a few days), 2 (more than half) and 3 (almost every day). The total score ranges from 0 to 27 (from the best to the worst). A score of 15 to 19 indicates moderate to severe depression and a score of 20 to 27 indicates severe depression.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Generalized Anxiety Disorder (GAD-7)
GAD-7 is a proven, self-administered and concise tool for screening and diagnosing mental health disorders, which has been tested in the field in office practice. The screening scale is easy to use and can be completed in a short time, which improves the recognition rate of anxiety disorders and facilitates diagnosis and treatment. The main statistical index of this scale is the total score, that is, the sum of item scores. The total score range of GAD-7 is 0: 21 and that of GAD-2 is 0: 6. The score of GAD-7 can be used to evaluate the severity of anxiety symptoms: 0: 4: no clinical significance: anxiety: 5: 9: mild; 10: 14: moderate; > 15: severe. When used as an assistant diagnosis of anxiety symptoms, the cut-off value of GAD-7 is greater than or equal to 10.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Functional Impairment Scale (FIS)
Functional impairment scale (FIS) is a 4-point scale to evaluate the functional status and injury intensity in daily activities. It can be used in conjunction with the four-point pain intensity scale, usually done daily and summarized within four weeks.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Euroqol-5 Dimension Questionnaire (EQ-5D)
EQ-5D-5Lis a general tool for assessing health status. EQ-5D-5Lconsists of two parts of EQ-5D description system and EQ VAS. The description system consists of five dimensions (activity ability, self-care, daily activities, pain / discomfort and anxiety / depression). Respondents need to tick (or cross) the corresponding boxes of the most appropriate declaration for each of the five dimensions to indicate their health status. The score of the EQ-5D description system generally ranges from 0 (death) to 1 (completely healthy). EQ VAS recorded the respondents' self-rated health outcomes through a vertical visual simulation scale, and the two endpoints were "imaginable ideal health state" and "imaginable least ideal health state". EQ VAS scores range from 0 (the least ideal state of health imaginable) to 100 (the most ideal state of health imaginable).
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Suicidal Ideation Score (C-SSRS Scale)
Suicidal ideation should be monitored in trials of central action drugs, higher scores mean a worse outcome.
Many migraine clinical trials used the Columbia suicide severity scale (C SSRS).The C-SSRS consists of a maximum of 20 items. C-SSRS will be administered in study subjects at each study visit to assess possible suicidal ideation and behavior. Reports of suicidal ideation with intent to act (endorse item 4 or 5) and reports of actual, aborted, or interrupted suicide attempts or a behavior preparatory for making an attempt indicate subjects at high risk for suicide.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Pulse Rate
Pulse rate will be measured during the visit.It means the number of heartbeats per minute, calculated with a stopwatch.Under normal circumstances, the pulse rate is consistent with the heart rate, and the normal range is 60-100 beats per minute. If it is greater than 100 beats per minute, it is called tachycardia. If it is less than 60 beats per minute, it is called bradycardia.
Record whether the pulse rate is normal, and describe in detail if abnormal. Record the number of people with clinically significant abnormal pulse rate.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Respiratory Rate
Respiratory rate will be measured during the visit.It means the number of breaths per minute, calculated with a stopwatch.Clinically, one inhalation and one exhalation are defined as one breath. The normal breathing rate is 12-20 breaths per minute.
Record whether the respiratory rate is normal, and describe in detail if abnormal.
Record the number of people with clinically significant abnormal respiratory rate.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Blood Pressure
Blood Pressure will be measured during the visit,including systolic blood pressure(SBP) and diastolic blood pressure(DBP). It can be calculated with a sphygmomanometer.
Blood pressure level classification for adults over 18 years old: normal blood pressure (SBP<120 mmHg and DBP<80 mmHg), high normal value [SBP 120-139 mmHg and (or) DBP 80-89 mmHg], hypertension [SBP≥140 mmHg] and (or) DBP≥90 mmHg].
Record whether the blood pressure is normal, and describe in detail if abnormal.
Record the number of people with clinically significant abnormal blood pressure.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Body Temperature
Body temperature will be measured during the visit.It can be calculated with a thermometer.The normal armpit body temperature of an average adult is 36-37°C.
Record whether the body temperature is normal, and describe in detail if abnormal.
Record the number of people with clinically significant abnormal body temperature.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Body Mass Index (BMI)
The following measurements are to be performed: height (initial screening only) and weight. Height and weight are to be measured without shoes. Body Mass Index (BMI) should be calculated using the following formula: BMI (kg/m2= weight (kg)/[height (cm)/100]2.
A normal BMI is between 20 and 25, over 25 is overweight and over 30 is obese.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Magnetic Resonance Imaging(MRI) T1
Patients will accept MRI scans. MRI T1 imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
MRI T2
Patients will accept MRI scans. MRI T2 imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
MRI T2 FLIAR
Patients will accept MRI scans. MRI T2 FLIAR imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Susceptibility weighted imaging(SWI) in MRI
Patients will accept MRI scans. SWI imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Arterial spin labeling(ASL) in MRI
Patients will accept MRI scans. ASL imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Diffusion Tensor Imaging(DTI) in MRI
Patients will accept MRI scans. DTI imaging data and description given by professional radiologist will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Echocardiography
Patients will accept Echocardiography. The degree of Right-to-left Shunt will be collected.
Measured: Medium term: within 6 months after initial diagnosis; long term: 60 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2022
- Study start12 Jul 2021
- Primary completion31 Dec 2082 (estimated)
- Study completion31 Dec 2082 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Headache Disorders, PrimaryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200,000 participants (estimated)
- Target duration
- 60 Years
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- First Affiliated Hospital of Zhejiang University, First People's Hospital of Hangzhou, Affiliated Hospital of Shaoxing Wenli University, Tiantai County People's Hospital, People's Hospital of Lin 'an City, Deqing County People's Hospital, Jiaxing No.1 Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Shaoxing People's Hospital, Huzhou Central Hospital, The Affiliated Hospital of Hangzhou Normal University, Quzhou City People's Hospital, Xin Hua Hospital of Zhejiang Province, The First People's Hospital of Huzhou, Zhongshan Hospital Of Traditional Chinese Medicine, Jiaxing Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Wenzhou Medical University, Affiliated Wenling Hospital of Wenzhou Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Linhai First People's Hospital, Pain Management Center, Stanford University, USA, The Second Affiliated Hospital of Jiaxing University, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Chongqing Xinqiao Hospital
- Responsible party
- Sponsor
- Investigators
- Kaiming Liu, Doctor, Principal investigator, headache specialist clinic of the Second Affiliated Hospital of Zhejiang Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05418218
- Sponsor's protocol ID
- 20220430
- Acronym
- IHRS
- Status last verified
- Oct 2024
- First submitted
- 30 Apr 2022
- Last updated
- 23 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- International Headache and Vertigo Registration Study
- ClinicalTrials.gov ID
- NCT05418218
- Acronym / sponsor ID
- IHRS / 20220430
- Conditions
- Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache, Vertigo, Vestibular Migraine
- Keywords
- Migraine, Headache Disorders, Vertigo, Vestibular Migraine, Fibromyalgia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200,000 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Collaborators
- First Affiliated Hospital of Zhejiang University, First People's Hospital of Hangzhou, Affiliated Hospital of Shaoxing Wenli University, Tiantai County People's Hospital, People's Hospital of Lin 'an City, Deqing County People's Hospital, Jiaxing No.1 Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Shaoxing People's Hospital, Huzhou Central Hospital, The Affiliated Hospital of Hangzhou Normal University, Quzhou City People's Hospital, Xin Hua Hospital of Zhejiang Province, The First People's Hospital of Huzhou, Zhongshan Hospital Of Traditional Chinese Medicine, Jiaxing Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Wenzhou Medical University, Affiliated Wenling Hospital of Wenzhou Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Linhai First People's Hospital, Pain Management Center, Stanford University, USA, The Second Affiliated Hospital of Jiaxing University, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Chongqing Xinqiao Hospital
- Study start
- 12 Jul 2021 (actual)
- Primary completion
- 31 Dec 2082 (estimated)
- Study completion
- 31 Dec 2082 (estimated)
- First posted
- 14 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.
Detailed description
- Research contents: In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.
- Research target:
We study biomarkers, imaging features, right-to-left shunt of heart (lung), genetic features, real-world treatment studies, and outcomes (in relation to other diseases) for headache and vertigo related diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 60 Years
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Migraine | – | –Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3. |
| Other Primary Headache Disorders | – | –Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3. |
| Vertigo | – | –Patients with other vertigo disorders (excluding vestibular migraine). |
| Secondary Headache Disorders | – | –Patients with secondary headache disorders as defined by ICHD-3. |
| Normal control | – | –Normal people do not have headache and vertigo. |
Who may qualify
- Ages
- 4 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Male or female participants ages 4 to 99 years
Key inclusion criteria (4 listed)
- Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.
- Male or female participants ages 4 to 99 years, inclusive, at Visit 1.
- Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).
Key exclusion criteria (2 listed)
- Patients who were unable to complete scales such as headache diary.
- Patients denied or unable to be admitted for long-term follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Days of Migraine
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
The number of days of migraine is the number of days in which migraine occurs or is likely to be migraine (according to IHS ICHD-3 diagnostic criteria). A migraine day is a day when a headache lasts for more than 30 minutes, does not take painkillers, and meets the ICHD-3 migraine or most likely migraine criteria. Migraine day can also be defined as a headache day that is effective for the acute treatment of specific migraine drugs (triptan, ditan, gepant, ergotamine, etc.).
Moderate / Severe Headache Days
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Moderate / severe headache days are defined as a day in which moderate or severe pain persists for at least 4 hours, or headache lasts for one day after successful medication for acute headache. These definitions allow the use of relatively simple headache diaries. Subjects were required to indicate whether headache was present (yes / no), peak (mild / moderate / severe) severity and duration (< 4h or 4h), type of acute drug intake (triptan ergot / other), and response to treatment should also be recorded.
Migraine Attack
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine attack is defined as any consistent migraine attacks or the use of specific migraine drugs. If a migraine attack is interrupted by sleep, or temporarily relieved, and then relapses within 48 hours, it is considered an attack. In addition, migraine attacks that were successfully treated with drugs but relapsed within 48 hours and lasted for more than 48 hours were counted as one attack.
26 secondary outcomes
The Response Rate of at Least 50%, 75% and 100% Reduction in the Number of Days of Migraine Attacks
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Headache Intensity
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Cumulative Hours of Moderate / Severe Pain at 28 Days
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Days Without Symptoms
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Days Without Headache
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Peak Headache Pain Intensity
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine Disability Assessment (MIDAS)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Headache Impact Scale (HIT-6)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Migraine Specific Quality of Life Questionnaire (MSQV2.1)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Patient Health Questionnaire (PHQ-9)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Generalized Anxiety Disorder (GAD-7)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Functional Impairment Scale (FIS)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Euroqol-5 Dimension Questionnaire (EQ-5D)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Suicidal Ideation Score (C-SSRS Scale)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Pulse Rate
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Respiratory Rate
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Blood Pressure
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Body Temperature
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Body Mass Index (BMI)
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Magnetic Resonance Imaging(MRI) T1
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
MRI T2
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
MRI T2 FLIAR
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Susceptibility weighted imaging(SWI) in MRI
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Arterial spin labeling(ASL) in MRI
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Diffusion Tensor Imaging(DTI) in MRI
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Echocardiography
Time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2025.
- Individual participant dataSharing planned: No
Related trials for Headache Disorders, Primary
RecruitingPhase 2/3
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
Migraine, With or Without Aura
Active, not recruitingPhase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Migraine
Not yet recruitingPhase 3
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Post Traumatic Headache
RecruitingObservational study
Overlapping Pain Trajectory Study
Migraine, Musculoskeletal Pain
RecruitingObservational study
(Italian Migraine Registry, I-GRAINE-NEW)
Migraine Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kaiming Liu, Doctor principal investigator
headache specialist clinic of the Second Affiliated Hospital of Zhejiang Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Headache Disorders, Primary and Headache Disorders, Secondary, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kaiming Liu, Doctor (+8615068862055, 2314411@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Days of Migraine (time frame: Medium term: within 6 months after initial diagnosis; long term: 60 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2025.